Skin Cancer-Focused Iovance Biotherapeutics Reports Better-Than-Expected 2024, 2025 Outlook, Stock Surges
Skin Cancer-Focused Iovance Biotherapeutics Reports Better-Than-Expected 2024, 2025 Outlook, Stock Surges
Iovance Biotherapeutics Inc (NASDAQ:IOVA) stock is trading higher on Friday after the company issued upbeat guidance for 2024 and 2025 and better-than-expected second-quarter earnings.
iovance biotherapeutics股票週五交易上漲，該公司發佈了2024年和2025年樂觀的指導方針和超預期的第二季度收益。
On Thursday, the cancer cell therapy maker Iovance reported second-quarter sales of $31.12 million, surpassing the consensus of $24.6 million.
癌症細胞治療製造商iovance週四公佈了第二季度銷售額爲3112萬美元，超過了2460萬美元的共識。
The company reported EPS loss of $(0.34), down from $(0.47) a year ago, beating the consensus of $(0.35).
該公司報告的每股收益虧損$(0.34)，低於去年的$(0.47)，擊敗了$(0.35)的共識。
Also Read: Iovance Biotherapeutics Price Forecast Slashed By 40% On Mutated Uptake For Its Newly Approved Skin Cancer Cell Therapy.
也可閱讀：iovance biotherapeutics新獲批皮膚癌細胞治療藥需要調整價格預測下調40％。
The second quarter of 2024 represents the first quarter of Amtagvi (lifileucel) sales in the U.S., with revenue of $12.8 million.
2024年第二季度代表了美國Amtagvi（lifileucel）銷售的第一季度，收入爲1280萬美元。
The quarter's product revenue includes $18.3 million in sales for Proleukin, which is used in the Amtagvi treatment regimen and global commercial and clinical uses in other settings.
該季度的產品收入包括Proleukin的銷售額達1830萬美元，該產品用於Amtagvi治療方案以及其他設置的全球商業和臨床應用。
As of July 24, Iovance had cash, cash equivalents, investments, and restricted cash of $449.6 million, expected to be sufficient to fund current and planned operations into early 2026.
截至7月24日，iovance擁有44960萬美元的現金、現金等價物、投資和受限現金，預計足以支持當前和計劃的運營工作至2026年初。
At the 2024 ASCO Annual Meeting, Iovance announced updated clinical data for treating frontline advanced melanoma.
在2024年ASCO年會上，iovance公佈了治療一線晚期黑色素瘤的更新臨床數據。
Guidance: Iovance expects significant quarter-over-quarter growth in product revenue to continue throughout 2024, 2025, and beyond as the adoption curve for Amtagvi steepens.
指導方針：iovance預計產品收入在2024年、2025年以及以後的季度將繼續顯著增長，因爲Amtagvi的採用曲線加速。
The company says over 55 patients have been infused with Amtagvi since the first commercial infusion in April 2024.
該公司表示，自2024年4月首次進行商業輸入以來，已有超過55名患者接受了Amtagvi的輸入。
The company says with utilization broadening and the rate of infusions substantially increasing, total infusions during the third quarter have markedly exceeded infusions in the second quarter.
該公司表示，隨着利用廣泛和輸入速度大幅增加，第三季度總輸入量顯著超過第二季度的輸入量。
Revenues are expected to be $53 million to $55 million in the third quarter, versus the consensus of $49.05 million.
第三季度的收益預計爲5300萬美元至5500萬美元，與4905萬美元的共識相比有所增加。
For fiscal year 2024, the company expects sales of $160 million to $165 million versus a consensus of $143.21 million.
對於2024財年，該公司預計銷售額爲16000萬美元至16500萬美元，而共識爲14321萬美元。
Iovance Biotherapeutics expects that growth for Amtagvi will continue as existing authorized treatment centers (ATC) demand increases and new ATCs are onboarded.
iovance biotherapeutics預計，Amtagvi的增長將繼續，因爲現有授權治療中心（ATC）的需求增加，新的ATC正在接入。
For fiscal 2025, product revenue is anticipated to be $450 million to $475 million, versus a consensus of $403.714 million. Gross margins are expected to increase to greater than 70% over the next several years.
對於2025財年，產品銷售額預計爲45000萬美元至47500萬美元，而共識爲40371.4萬美元。毛利率預計在未來幾年將增加至70%以上。
Price Action: IOVA stock is up 25.19% at $9.94 at last check Friday.
股價表現：IOVA股票在上週五最後一次查看時上漲25.19％，達到9.94美元。
- What's Going On With Trump Media Stock On Friday?
- 特朗普媒體股票週五的情況如何？
Photo: Shutterstock
Photo: shutterstock